|
|
 |
|
Viewing report
|
|
|
|
Schizophrenia Therapeutics Market in the US: Market Forecast, Patient Flow, and Competitive Landscape
Commercial Insights, May 2011, Pages: 73
The global schizophrenia therapeutics market was valued at $6.7 billion in 2010, and is expected to reach $7.3 billion by 2018, increasing at a CAGR of 7.5% between 2010 and 2018. The US schizophrenia therapeutics market is expected to increase at a CAGR of 4.5%. The patent expiration of many leading schizophrenia therapies in the US will result in their mass genericization.
However, factors such as rising schizophrenia prevalence, along with an increasing schizophrenia diagnosis rate and schizophrenia treatment rates, will offset the declining market. Also, the report foresees the rapid uptake of Invega Sustenna and some of the high potential pipeline molecules, as significant market events contributing to higher sales revenues.
Research Scope:
- Geographies Covered: The US
- Forecast Period: 8 Years (2010 to 2018)
Market Analysis:
- Schizophrenia therapeutics market size and forecast – Global and the US
- Insights into market events that impact the schizophrenia therapeutics market – The US
- Leading therapies – Global and the US
Competitive Landscape Analysis:
- Market share insights of leading brands – Global and the US
- Future market share analysis of the global schizophrenia therapeutics market
- Profiles of leading brands by annual therapy cost and their market shares
- Market share analysis of the schizophrenia therapeutics market in the US
Patient Flow Analysis:
- Patient flow study with diagnosis rate and treated population rate – Global and the US
- Analysis and forecasts of schizophrenia prevalence population – Global and the US
- Analysis and forecasts of schizophrenia diagnosis population – Global and the US
- Analysis and forecasts of schizophrenia treated population – Global and the US
Unmet Need:
- Unmet need analysis of the global schizophrenia therapeutics market
Pipeline Analysis:
- Analysis of schizophrenia pipeline molecules by phase of development
- Detailed clinical profiles of high potential phase 3 molecules
Product samples
A sample for this product is available. Please Login/Register to download this sample.
|
|
|
|
